4/6/2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Rare Disease and Endocrinology Portfolio
The acquisition adds VYKAT™ XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), to Neurocrine’s growing portfolio of first-in-class therapies.
0
4 min read